Arase Therapeutics




Cambridge, Massachusetts
Arase Therapeutics is developing small molecule therapeutics for oncology. Their molecules enable the inhibition of PARP, an enzyme that acts as a first responder in the DNA damage response. Incancer cells, PARP enzymes are essential to DNA repair and enabling tumor cells to continue celldivision. Arase is developing a novel approach to PARP inhibition that may overcome resistance thatdevelops in certain cancer cells. If Arase is successful, their therapeutic will provide an alternatetreatment option for patients whose cancer does not respond to current PARP inhibitor therapies.

Paul Chang

Stay Tuned

Subscribe to our newsletter and get updates on our portfolio companies.